Table 3. Response and disease control rates in EGFR-mutant NSCLC patients treated with EGFR-TKIs with or without metformin.
| Response | First-line EGFR-TKIs | Second-line Osimertinib | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Total N=85 | Metformin use | P | Total N=22 | Metformin use | P | ||||
| Yes | No | Yes | No | ||||||
| CR | — | — | — | — | — | — | |||
| PR | 51 | 24 | 27 | 10 | 6 | 4 | |||
| SD | 31 | 4 | 27 | 10 | 4 | 6 | |||
| PD | 3 | — | 3 | 2 | — | 2 | |||
| ORR | 60.0% | 85.7% | 47.4% | 0.001 | 45.5% | 60.0% | 33.3% | 0.412 | |
| DCR | 96.5% | 100.0% | 94.7% | 0.548 | 90.9% | 100.0% | 83.3% | 0.481 | |
EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; progression-free survival; ORR, objective response rate; DCR, disease control rate.